Trial Profile
A Phase III, Randomized, Two-armed, Triple Blinded, Parallel, Active Controlled Non-Inferiority Clinical Trial of AryoTrust (AryoGen Trastuzumab) Efficacy and Safety in Comparison to Herceptin (Genentech) in HER2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors AryoGen Pharmed
- 08 Jul 2020 Status changed from active, no longer recruiting to completed.
- 05 Feb 2019 Planned End Date changed from 30 Oct 2018 to 6 Mar 2019.
- 05 Feb 2019 Planned primary completion date changed from 30 Oct 2018 to 6 Mar 2019.